Ravi Salgia, MD, PhD

Ravi Salgia M.D., Ph.D., is the Arthur & Rosalie Kaplan Chair in Medical Oncology and the associate director for clinical sciences research in City of Hope's Comprehensive Cancer Center.

Prior to joining City of Hope, Dr. Salgia served as tenured professor of medicine, pathology and dermatology; director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology; vice chair for translational research in the department of medicine; and associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago.

Dr. Salgia earned his undergraduate summa cum laude in mathematics, biology, and chemistry, and then his medical doctorate and Ph.D. from Loyola University in Chicago, IL, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins Hospital in Baltimore, MD, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, MA, during which time he also served as a clinical fellow at Harvard Medical School in Boston, MA.

Board-certified in both internal medicine and medical oncology, Dr. Salgia serves on various panels for the National Cancer Institute. He has consistently received research grants from the NIH for his research work and has been awarded several invention discoveries and patents related to his work. He is the current Chief Editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis. Dr. Salgia also serves on the editorial advisory board of four additional journals. He has authored 286 peer-reviewed articles, reviews and editorials, one book, and 34 book chapters.

Dr. Salgia is frequently invited to present his work at national and international conferences and symposia and is the recipient of several honors and awards including pμƐ National Competition in Mathematics, Richard V. Andree Award for “Volume of an n-Dimensional Unit Sphere”; serving as a chartered member of NIH/NCI’s Tumor Progression and Metastasis Study Section; and he was also elected as the Translational Science Representative on the Thoracic Malignancy Steering Committee of the NCI.